Skip to main content

Gamida Cell Ltd.

GMDADelisted Apr 25, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001600847

Gamida Cell Ltd. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Feb 2, 2024; 52 institutions reported holding it in 13F filings for Q1 2024, worth $697.9K in total; ARK Invest was the only superinvestor holding it.

Q1 2024 vs. Q4 2023

How the institutions holding Gamida Cell Ltd. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of GMDA: Q4 2023 compared with Q1 2024
MeasureQ4 2023Of which not filed for Q1 2024Q1 2024Change
Holders52152+1
Shares31.9M87.4K19.4M−12.4M (−39.1%)
Value$13.2M$33.1K$697.9K−$12.4M (−94.7%)

1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (10)

Institutions that held Gamida Cell Ltd. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to GMDA in Q1 2024
InstitutionSharesValue% of portfolio
StoneX Group Inc.793,958$28.7K0.00%
UBS Group AG201,000$7.24K0.00%
Two Sigma Securities, LLC143,568$5.18K0.00%
XTX Topco Ltd135,773$4.90K0.00%
Virtu Financial LLC92,745$3.00K0.00%
CVI Holdings, LLC53,000$1.91K0.00%
HRT Financial LP43,366$1.00K0.00%
Citadel Advisors LLC18,890$6820.00%
Envestnet Asset Management Inc10,000$3610.00%
Mercer Global Advisors Inc10,000$00.00%

Sold out (9)

Institutions that held Gamida Cell Ltd. at the end of Q4 2023 and filed for Q1 2024 without it.

Not filed for Q1 2024 yet (1)

Institutions that held Gamida Cell Ltd. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding GMDA in Q4 2023 that haven't filed for Q1 2024
InstitutionShares, Q4 2023Value, Q4 2023
Platform Technology Partners87,353$33.1K